I candidati vaccini contro la COVID-19 testati nell'uomo sono elencati in fondo a questa pagina.

Ad oggi, la Confederazione ha stipulato contratti con cinque produttori: Moderna (ormai 20,5 milioni di dosi in totale), Pfizer/BioNTech (circa 6 milioni di dosi), AstraZeneca (circa 5,3 milioni di dosi) e ora Curevac (5 milioni di dosi) e Novavax (6 milioni di dosi). Questa strategia assicura che anche in caso di difficoltà di consegna, la popolazione abbia a disposizione dosi sufficienti di un vaccino autorizzato. La Confederazione continua a intrattenere negoziati con vari produttori, poiché è difficile valutare come si svilupperà la pandemia. 

Le pubblicazioni scientifiche (peer-reviewed) e/o i comunicati stampa disponibili per questi vaccini sono i seguenti.

 

mRNA-1273 (ARNm, Moderna et National Institute of Allergy e Infectious Diseases et Moderna)

An mRNA Vaccine against SARS-CoV-2 — Preliminary Report (New England Journal of Medicine, 14.7.2020)

Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults (New England Journal of Medicine, 29.9.2020)

Moderna Announces Primary Efficacy Analysis in Phase 3 COVE Study for Its COVID-19 Vaccine Candidate and Filing Today with U.S. FDA for Emergency Use Authorization (30.11.2020)

Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination (New England Journal of Medicine, 4.12.2020)

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine (New England Journal of Medicine, 30.12.2020)

A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine (Vaccine, 9.2.2021)

Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19 (New England Journal of Medicine, 6.4.2021)

Neutralization of SARS-CoV-2 Variants B.1.429 and B.1.351 (New England Journal of Medicine, 7.4.2021)

Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons (New England Journal of Medicine, 21.4.2021)

Moderna Announces Positive Initial Booster Data Against SARS-CoV-2 Variants of Concern (Press release, 5.5.2021)

Moderna Announces TeenCOVE Study of its COVID-19 Vaccine in Adolescents Meets Primary Endpoint and Plans to Submit Data to Regulators in Early June (Press release, 25.5.2021)

 

BNT162b2 (ARNm, BioNTech RNA Pharmaceuticals e Pfizer)

Phase 1/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim Report (1.7.2020)

Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults (Nature, 12.8.2020)

COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T-cell responses (Nature, 30.9.2020)

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates (New England Journal of Medicine, 14.10.2020)

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine (New England Journal of Medicine, 10.12.2020)

BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting (New England Journal of Medicine, 24.2.2021)

Neutralizing Activity of BNT162b2-Elicited Serum (New England Journal of Medicine, 8.3.2021)

Pfizer and BioNTech Confirm High Efficacy and No Serious Safety Concerns Through Up to Six Months Following Second Dose in Updated Topline Analysis of Landmark COVID-19 Vaccine Study (Press release, 1.4.2021)

Neutralizing Response against Variants after SARS-CoV-2 Infection and One Dose of BNT162b2 (New England Journal of Medicine, 7.4.2021)

Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons (New England Journal of Medicine, 21.4.2021)

Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-blind phase 1 study (Nature Medicine, 22.4.2021)

COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study (Lancet, 23.4.2021)

Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study (Lancet, 23.4.2021)

Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study (Lancet Infectious Diseases, 27.4.2021)

Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data (Lancet, 5.5.2021)

Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants (New England Journal of Medicine, 5.5.2021)

BNT162b2-Elicited Neutralization against New SARS-CoV-2 Spike Variants (New England Journal of Medicine, 12.5.2021)

Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents (New England Journal of Medicine, 27.5.2021)

Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination (The Lancet, 3.6.2021)

 

AZD1222 (ChAdOx1 nCoV-19) (vettore vaccinaleAstra Zeneca e University of Oxford)

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial (The Lancet 20.7.2020)

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial (The Lancet, 18.11.2020)

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK (The Lancet, 8.12.2020)

T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial et Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses (Nature Medicine, 17.12.2020)

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials (The Lancet, 19.2.2021)

Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant (NEJM, 16.3.2021)

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial (The Lancet, 30.3.2021)

Thromboembolism and the Oxford–AstraZeneca COVID-19 vaccine: side-effect or coincidence? (The Lancet, 30.3.2021)

Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination (New England Journal of Medicine, 9.4.2021)

Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination (New England Journal of Medicine, 9.4.2021)

Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study (Lancet, 23.4.2021)

Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study (Lancet Infectious Diseases, 27.4.2021)

 

Poiché i vaccini di Moderna, Pfizer/BioNTech e AstraZeneca sono già stati concessi in licenza in alcuni paesi, una sintesi dei risultati provvisori delle prove di fase 3 già disponibili per questi vaccini è disponibile ICI.

 
CVnCoV Vaccine (mRNA, Curevac)
 
 
 
 

 

 
NVX-CoV2373 (proteine ricombinanti, Novavax)

Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (New England Journal of Medicine, 2.9.2020)

Novavax COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Trial (Press release, 28.1.2021)

Novavax Confirms High Levels of Efficacy Against Original and Variant COVID-19 Strains in United Kingdom and South Africa Trials  (Press release, 11.3.2021)

Neutralization of SARS-CoV-2 Variants B.1.429 and B.1.351 (New England Journal of Medicine, 7.4.2021)

Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (New England Journal of Medicine, 5.5.2021)

Efficacy of the NVX-CoV2373 Covid-19 Vaccine Against the B.1.1.7 Variant (medRxiv, 14.5.2021)

Novavax Announces Positive Data from Three Complementary Studies of COVID-19 Beta (B.1.351) Variant Strain Vaccine (Press release, 11.6.2021)

Novavax COVID-19 Vaccine Demonstrates 90% Overall Efficacy and 100% Protection Against Moderate and Severe Disease in PREVENT-19 Phase 3 Trial (Press release, 14.6.2021)

 
 

Altri vaccini già nella Fase III (efficacia e sicurezza)

Nota: alcuni di questi vaccini sono già stati autorizzati in alcuni paesi. Per una lista attuale dei vaccini in sperimentazione clinica, vedi questo documento dell'OMS regolarmente aggiornato.

 

Inactivated SARS-CoV-2 (virus inattivato, Sinovac e Butantan Institute)

Inactivated Novel Coronavirus Pneumonia (COVID-19) vaccine (virus inattivato,  Hennan Provincial Center for Disease Control and Prevention e Sinopharm)

- BBIBP-CorV (virus inattivato, Beijing Institute of Biological Products Co., LTD e Laboratorio Elea Phoenix S.A.)

Ad26.COV2.S (vettore vaccinale, Janssen Vaccines & Prevention (Johnson & Johnson))

Ad5-nCoV (vettore vaccinale, CanSino Biologics)

- Gam-COVID-Vac (vettore vaccinale, Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation)

- Inactivated Novel Coronavirus Pneumonia (COVID-19) vaccine (Vero cells) (virus inattivato, Wuhan Provincial Center for Disease Control and Prevention)

- CoVLP (proteine ricombinanti, Medicago)

BBV152 - COVAXIN (virus inattivato, Bharat Biotech International Ltd)

Recombinant new coronavirus vaccine (CHO cell) (proteine ricombinanti, Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.)

- AG0302-COVID19 (DNA, AnGes Inc., Japan Agency for Medical Research and Development)

Inactivated SARS-CoV-2 Vaccine (virus inattivato, Chinese Academy of Medical Sciences)

- SCB-2019 (proteine ricombinanti, Clover Biopharmaceuticals Australia)

nCov Vaccine (DNA, Cadila Healthcare Ltd)

- QazCovid-in (virus inattivato, Research Institute for Biological Safety Problems)

- UB-612 (proteine ricombinanti, United Biomedical, COVAXX)

- EpiVacCorona (proteine ricombinanti, Federal Budgetary Research Institution State Research Center of Virology and Biotechnology "Vector")

 Elenco continuamente aggiornato di vaccini in fase III (in inglese)

 

Questi vaccini, e quelli ancora in fase I o II, sono descritti di seguito:

  • 1

Labels HONcode

Aderiamo allo standard HONcode per l'affidabilità dell'informazione medica Aderiamo allo standard HONcode per l'affidabilità dell'informazione medica.
Vedere il certificato

Questo sito è stato certificato dall’Organizzazione Mondiale della Sanità (OMS) e adempie a tutti i criteri di buona pratica  in materia d’informazione sulle vaccinazioni.

Per saperne di più...